程序性死亡配体 1 表达和 CD8+肿瘤浸润淋巴细胞在微波消融联合化疗治疗晚期非小细胞肺癌中的作用。

Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy.

机构信息

a Department of Oncology , Shandong Provincial Hospital Affiliated to Shandong University , Shandong Province , China.

b Department of Pathology , Linyi People's Hospital , Shandong Province , China.

出版信息

Int J Hyperthermia. 2018;35(1):591-598. doi: 10.1080/02656736.2018.1513169. Epub 2018 Oct 11.

DOI:10.1080/02656736.2018.1513169

PMID:30307348

Abstract

BACKGROUND

Programmed death-ligand 1 (PD-L1) and CD8+ tumor-infiltrating lymphocytes (TILs) were associated with non-small cell lung cancer (NSCLC). We conducted this study to evaluate the correlation between PD-L1 or CD8+ TILs expression and MWA or survival in advanced NSCLC patients treated with microwave ablation (MWA) plus chemotherapy.

METHODS

Previously untreated, pathologically verified advanced NSCLC patients with adequate tissues for the analysis of PD-L1 expression and the presence of CD8+ TILs were retrospectively enrolled. None of the patients had sensitive mutations, and therefore, they were treated with MWA of the primary tumors followed by chemotherapy.

RESULTS

A total of 51 patients were enrolled. PD-L1 expression and the presence of CD8+ TILs were identified in 31 (60.8%) and 9 (17.6%) patients, respectively. PD-L1 expression and CD8+ TILs had no correlation with baseline characteristics, the response to chemotherapy or MWA. Patients with PD-L1 expression had similar progression-free survival (PFS: 7.9 months for PD-L1-positive vs. 5.8 months for PD-L1-negative; p = .660) and overall survival (OS: 18.7 months for PD-L1-positive vs. 15.2 months for PD-L1-negative; p = .901). Patients with CD8+ TIL expression did not show superior PFS (CD8+ TIL vs. CD8- TIL, 8.0 vs. 6.2 months, p = .435) or OS (CD8+ TIL vs. CD8- TIL, 20.5 vs. 16.9 months, p = .653).

CONCLUSION

PD-L1 expression and the presence of CD8+ TILs could predict neither the patients' response to chemotherapy or MWA nor survival in advanced NSCLC patients treated with MWA plus chemotherapy.

摘要

背景

程序性死亡配体 1（PD-L1）和 CD8+肿瘤浸润淋巴细胞（TILs）与非小细胞肺癌（NSCLC）相关。我们进行这项研究，以评估 PD-L1 或 CD8+TILs 表达与微波消融（MWA）联合化疗治疗的晚期 NSCLC 患者的 MWA 或生存之间的相关性。

方法

回顾性纳入先前未经治疗、经病理证实的晚期 NSCLC 患者，这些患者有足够的组织用于分析 PD-L1 表达和 CD8+TILs 的存在。这些患者均无敏感突变，因此接受 MWA 治疗原发性肿瘤，然后进行化疗。

结果

共纳入 51 例患者。分别有 31 例（60.8%）和 9 例（17.6%）患者存在 PD-L1 表达和 CD8+TILs。PD-L1 表达和 CD8+TILs 与基线特征、对化疗或 MWA 的反应均无相关性。PD-L1 表达阳性患者的无进展生存期（PFS：PD-L1 阳性患者为 7.9 个月，PD-L1 阴性患者为 5.8 个月；p=0.660）和总生存期（OS：PD-L1 阳性患者为 18.7 个月，PD-L1 阴性患者为 15.2 个月；p=0.901）相似。CD8+TIL 表达患者的 PFS 也无优势（CD8+TIL 与 CD8-TIL，8.0 与 6.2 个月，p=0.435）或 OS（CD8+TIL 与 CD8-TIL，20.5 与 16.9 个月，p=0.653）。